


Suggested treatment pathway for anticoagulation for stroke prevention in atrial fibrillation (SPAF)



More information on anticoagulation in AF can be found at www.slcsn.nhs.uk/af/, including

- SLCSN AF pathway
- Guidance on stroke risk assessment in AF including CHADS₂ and bleeding risk assessment
- Position statement on NOACs
- Prescribing guidance for individual NOACs
- Transfer of care guidance for NOACs

¹ Such as intolerable rash, significant alopecia, skin necrosis

² Inability to comply with warfarin monitoring may be due to lack of understanding of the monitoring process or inability to access any local monitoring service (this should be discussed with the patient's own GP, before a NOAC is initiated).

³ Unable to achieve a satisfactory INR after an adequate trial of warfarin (usually at least 3 months) despite compliance with drug therapy. Patients at particular risk are those that remain sub-therapeutic (INR persistently < 2), those where the INR regularly fluctuates above 4 and those requiring dosages at the extreme ends of the dose range.